Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF_FRontier-1: LY4152199 in Previously Treated B-cell Malignancies
NCT07101328Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 12
01
Overview
Phase 1, open-label trial of LY4152199 in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 3 more (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Dose Limiting Toxicities at 35 days. Started May 2026; status: recruiting.
02
Drugs
LY4152199
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07101328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101328.